In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 1 to 10 of 123

TitleTypeExpected publication date
Abemaciclib with abiraterone acetate and prednisone for treating hormone-relapsed metastatic prostate cancer [ID6230]Technology appraisal guidanceTBC
Abemaciclib with fulvestrant for previously treated hormone receptor-positive HER2-negative advanced breast cancer TSID 12065Technology appraisal guidanceTBC
Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer ID6339Technology appraisal guidance
Advanced breast cancer: diagnosis and management (Partial update)NICE guidelineTBC
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110]Technology appraisal guidance
Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer ID6256Technology appraisal guidance
Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215]Technology appraisal guidanceTBC
Artificial intelligence (AI) technologies for assessing and triaging skin lesions within the urgent suspected skin cancer pathwayHealth technology evaluation
Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer TS ID 10701Technology appraisal guidanceTBC
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for early triple negative breast cancer [ID6200]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All